vs
Apellis Pharmaceuticals, Inc.（APLS）与ONITY GROUP INC.（ONIT）财务数据对比。点击上方公司名可切换其他公司
ONITY GROUP INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$290.0M vs $199.9M），ONITY GROUP INC.净利率更高（43.9% vs -29.5%，领先73.4%），ONITY GROUP INC.同比增速更快（29.0% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-750.9M），过去两年ONITY GROUP INC.的营收复合增速更高（10.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
奥尼提集团（原奥克文）是一家提供住宅及商业抵押贷款 servicing、特殊 servicing以及资产管理服务的供应商，业务性质也可概括为向房主收取每月本金与利息。公司成立于1988年，总部位于佛罗里达州西棕榈滩，在美国多地及菲律宾、印度都设有办公及支持运营点。
APLS vs ONIT — 直观对比
营收规模更大
ONIT
是对方的1.5倍
$199.9M
营收增速更快
ONIT
高出34.9%
-5.9%
净利率更高
ONIT
高出73.4%
-29.5%
自由现金流更多
APLS
多$736.6M
$-750.9M
两年增速更快
ONIT
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $290.0M |
| 净利润 | $-59.0M | $127.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 43.9% |
| 营收同比 | -5.9% | 29.0% |
| 净利润同比 | -62.2% | 552.7% |
| 每股收益（稀释后） | $-0.40 | $14.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSONIT
| Q4 25 | $199.9M | $290.0M | ||
| Q3 25 | $458.6M | $280.3M | ||
| Q2 25 | $178.5M | $246.6M | ||
| Q1 25 | $166.8M | $249.8M | ||
| Q4 24 | $212.5M | $224.8M | ||
| Q3 24 | $196.8M | $265.7M | ||
| Q2 24 | $199.7M | $246.4M | ||
| Q1 24 | $172.3M | $239.1M |
净利润APLSONIT
| Q4 25 | $-59.0M | $127.2M | ||
| Q3 25 | $215.7M | $18.7M | ||
| Q2 25 | $-42.2M | $21.5M | ||
| Q1 25 | $-92.2M | $22.1M | ||
| Q4 24 | $-36.4M | $-28.1M | ||
| Q3 24 | $-57.4M | $21.4M | ||
| Q2 24 | $-37.7M | $10.5M | ||
| Q1 24 | $-66.4M | $30.1M |
营业利润率APLSONIT
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | 3.6% | ||
| Q4 24 | -12.3% | -14.9% | ||
| Q3 24 | -24.0% | 10.4% | ||
| Q2 24 | -14.7% | 5.5% | ||
| Q1 24 | -36.0% | 13.3% |
净利率APLSONIT
| Q4 25 | -29.5% | 43.9% | ||
| Q3 25 | 47.0% | 6.7% | ||
| Q2 25 | -23.6% | 8.7% | ||
| Q1 25 | -55.3% | 8.8% | ||
| Q4 24 | -17.1% | -12.5% | ||
| Q3 24 | -29.2% | 8.1% | ||
| Q2 24 | -18.9% | 4.3% | ||
| Q1 24 | -38.5% | 12.6% |
每股收益（稀释后）APLSONIT
| Q4 25 | $-0.40 | $14.53 | ||
| Q3 25 | $1.67 | $2.03 | ||
| Q2 25 | $-0.33 | $2.40 | ||
| Q1 25 | $-0.74 | $2.50 | ||
| Q4 24 | $-0.30 | $-3.59 | ||
| Q3 24 | $-0.46 | $2.65 | ||
| Q2 24 | $-0.30 | $1.33 | ||
| Q1 24 | $-0.54 | $3.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $180.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $627.9M |
| 总资产 | $1.1B | $16.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSONIT
| Q4 25 | $466.2M | $180.5M | ||
| Q3 25 | $479.2M | $172.8M | ||
| Q2 25 | $370.0M | $194.3M | ||
| Q1 25 | $358.4M | $178.0M | ||
| Q4 24 | $411.3M | $184.8M | ||
| Q3 24 | $396.9M | $201.6M | ||
| Q2 24 | $360.1M | $203.1M | ||
| Q1 24 | $325.9M | $185.1M |
总债务APLSONIT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSONIT
| Q4 25 | $370.1M | $627.9M | ||
| Q3 25 | $401.2M | $501.4M | ||
| Q2 25 | $156.3M | $481.9M | ||
| Q1 25 | $164.2M | $460.2M | ||
| Q4 24 | $228.5M | $442.9M | ||
| Q3 24 | $237.1M | $468.2M | ||
| Q2 24 | $264.3M | $446.2M | ||
| Q1 24 | $266.7M | $432.1M |
总资产APLSONIT
| Q4 25 | $1.1B | $16.2B | ||
| Q3 25 | $1.1B | $16.1B | ||
| Q2 25 | $821.4M | $16.5B | ||
| Q1 25 | $807.3M | $16.3B | ||
| Q4 24 | $885.1M | $16.4B | ||
| Q3 24 | $901.9M | $13.2B | ||
| Q2 24 | $904.5M | $13.1B | ||
| Q1 24 | $831.9M | $13.1B |
负债/权益比APLSONIT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-748.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-750.9M |
| 自由现金流率自由现金流/营收 | -7.1% | -258.9% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | -5.88× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSONIT
| Q4 25 | $-14.2M | $-748.0M | ||
| Q3 25 | $108.5M | $229.5M | ||
| Q2 25 | $4.4M | $-598.8M | ||
| Q1 25 | $-53.4M | $-148.1M | ||
| Q4 24 | $19.4M | $-573.8M | ||
| Q3 24 | $34.1M | $19.2M | ||
| Q2 24 | $-8.3M | $-77.9M | ||
| Q1 24 | $-133.0M | $-297.1M |
自由现金流APLSONIT
| Q4 25 | $-14.3M | $-750.9M | ||
| Q3 25 | $108.3M | $228.8M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | $-148.4M | ||
| Q4 24 | $19.3M | $-574.6M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | $-8.4M | $-78.0M | ||
| Q1 24 | $-133.3M | $-297.2M |
自由现金流率APLSONIT
| Q4 25 | -7.1% | -258.9% | ||
| Q3 25 | 23.6% | 81.6% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | -59.4% | ||
| Q4 24 | 9.1% | -255.6% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | -4.2% | -31.7% | ||
| Q1 24 | -77.3% | -124.3% |
资本支出强度APLSONIT
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率APLSONIT
| Q4 25 | — | -5.88× | ||
| Q3 25 | 0.50× | 12.27× | ||
| Q2 25 | — | -27.85× | ||
| Q1 25 | — | -6.70× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.90× | ||
| Q2 24 | — | -7.42× | ||
| Q1 24 | — | -9.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ONIT
暂无分部数据
